845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article